Wu Feng, Qiu Yihua, Ye Guangming, Luo Hede, Jiang Junsong, Yu Feng, Zhou Wei, Zhang Shuai, Feng Jinzhong
Department of Cardiology, 98th Military Hospital, Huzhou 313000, China.
Department of Stomatology, 98th Military Hospital, Huzhou 313000, China.
Cardiovasc Pathol. 2015 Sep-Oct;24(5):294-303. doi: 10.1016/j.carpath.2015.04.008. Epub 2015 Apr 28.
Diabetic cardiomyopathy, a disorder of the heart muscle in diabetic patients, is one of the major causes of heart failure. The aim of present study was to investigate the therapeutic effect of hydrogen molecule on streptozotocin-induced diabetic cardiomyopathy in mice.
Diabetes was induced in adult male mice by consecutive peritoneal injection of streptozotocin (50 mg/kg/day) for 5 days. Then, they were treated with hydrogen water (1.3±0.2 mg/l) for 8 weeks (four groups, n=83-88 in each group).
Although treatment of diabetic mice with hydrogen water did not significantly affect blood glucose level, it significantly attenuated cardiac hypertrophy and reduced expression of atrial natriuretic factor and β-myosin heavy chain; it alleviated cardiac fibrosis and reduced expression of collagen I and III, transforming growth factor beta, alpha-smooth muscle actin, and osteopontin; it reduced cardiac caspase-3 activity and ratio of bax/bcl-2. Importantly, hydrogen water treatment improved cardiac function in streptozotocin-diabetic mice. Furthermore, it was found that hydrogen water treatment abated oxidative stress, suppressed inflammation, and attenuated endoplasmic reticulum stress in the hearts of streptozotocin-diabetic mice. In addition, hydrogen water treatment suppressed activation of Jun NH2-terminal kinase and p38 mitogen activated protein kinase signaling and nuclear factor κB signaling in the hearts of streptozotocin-diabetic mice.
Treatment with hydrogen molecule attenuated cardiac dysfunction in streptozotocin-induced diabetic mice, which was independent of glycemic control.
Treatment with hydrogen molecule attenuated cardiac dysfunction in streptozotocin-induced type 1 diabetic mice. Molecular hydrogen could thus be envisaged as a nutritional countermeasure for diabetic cardiomyopathy.
糖尿病性心肌病是糖尿病患者心肌的一种病症，是心力衰竭的主要原因之一。本研究的目的是探讨氢分子对链脲佐菌素诱导的小鼠糖尿病性心肌病的治疗作用。
通过连续5天腹腔注射链脲佐菌素（50mg/kg/天）诱导成年雄性小鼠患糖尿病。然后，用氢水（1.3±0.2mg/l）对它们进行8周的治疗（四组，每组n=83-88）。
虽然用氢水处理糖尿病小鼠对血糖水平没有显著影响，但它显著减轻了心脏肥大，降低了心房利钠因子和β-肌球蛋白重链的表达；减轻了心脏纤维化，降低了I型和III型胶原蛋白、转化生长因子β、α-平滑肌肌动蛋白和骨桥蛋白的表达；降低了心脏半胱天冬酶-3活性和bax/bcl-2比值。重要的是，氢水处理改善了链脲佐菌素诱导的糖尿病小鼠的心脏功能。此外，发现氢水处理减轻了氧化应激，抑制了炎症，并减轻了链脲佐菌素诱导的糖尿病小鼠心脏中的内质网应激。此外，氢水处理抑制了链脲佐菌素诱导的糖尿病小鼠心脏中Jun氨基末端激酶和p38丝裂原活化蛋白激酶信号通路以及核因子κB信号通路的激活。
氢分子治疗减轻了链脲佐菌素诱导的糖尿病小鼠的心脏功能障碍，这与血糖控制无关。
氢分子治疗减轻了链脲佐菌素诱导的1型糖尿病小鼠的心脏功能障碍。因此，分子氢可被设想为糖尿病性心肌病的一种营养对策。
